Ghrelin vs Triptorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Ghrelin
Endogenous 28-amino acid peptide secreted primarily by the stomach that functions as both the primary hunger signal and a potent growth hormone secretagogue. The n-octanoyl modification at Ser-3 (acylated form) is required for GHS-R1a receptor binding and GH-stimulating activity. Understanding ghrelin explains the mechanism behind the entire GHRP class of research peptides.
Full profileTriptorelin
Potent synthetic GnRH agonist approximately 100× more potent than native GnRH. Used clinically for prostate cancer, endometriosis, and precocious puberty via sustained suppression. A single low dose (100mcg IM) is studied as a 'PCT restart' strategy that exploits the initial LH/FSH flare before receptor desensitization sets in.
Full profile| Ghrelin | Triptorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | GHRL, growth hormone-releasing peptide endogenous, ghrelinergic peptide, acyl ghrelin | GnRH agonist, Decapeptyl, Trelstar, D-Trp6-LHRH |
| Evidence | Investigational (in trials) | Research-stage |
| Dosing range | 0.5mcg/kg–2mcg/kg mcg/kg, IV or SC bolus; endogenous levels peak pre-meal | 50mcg–200mcg mcg, Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical) |
| Administration | Intravenous (research), Subcutaneous injection | Intramuscular injection, Subcutaneous injection |
| Key side effects | Appetite stimulation, Transient hyperglycemia, Water retention, GH pulse stimulation | Initial testosterone surge followed by suppression (with repeated dosing), Hot flashes, Decreased libido, Bone density loss (long-term repeated dosing) |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: Ghrelin is investigational (in trials), while Triptorelin is research-stage.
- Administration: Ghrelin — Intravenous (research), Subcutaneous injection; Triptorelin — Intramuscular injection, Subcutaneous injection.
- Dosing units differ: Ghrelin is dosed in mcg/kg, Triptorelin in mcg — they operate at different scales.
- Frequency: Ghrelin is typically IV or SC bolus; endogenous levels peak pre-meal; Triptorelin is Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical).
How each works
Ghrelin
Ghrelin was discovered in 1999 as the endogenous ligand for the GHS-R1a receptor. Its acylated form activates GH release from the pituitary, stimulates appetite via NPY/AgRP hypothalamic neurons, and modulates energy homeostasis and fat storage. The des-acyl form (majority of circulating ghrelin) lacks GHS-R1a activity but has independent cardiovascular and cellular effects.
Triptorelin
Triptorelin produces a biphasic response: an initial agonist surge of LH and FSH (the 'flare effect') followed by complete pituitary desensitization with continued use. The single-dose PCT protocol leverages only the initial flare to jumpstart testosterone production. Clinical data supports LH surges of 10–20× baseline within hours of the first dose.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.